HBVtech is recommended for FY22 Discovery Award, a part of peer reviewed medical research program under CDMAP managed by DoD.

Nov 3, 2022

This is the 2nd Discovery Award to HBVtech

The intent of the Discovery Award under FY22 Peer Reviewed Medical Research Program (PRMRP) is to support innovative, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications.

HBVtech submitted the application titled” Investigating if HBV cccDNA is the 1st viral DNA species cleared from infected cells” in Mat 2022 and was recommended in October for funding after two vigorous scientific and programmatic review processes.

HBVtech was awarded the 1st Discovery Award in 2020.

https://cdmrp.health.mil/prmrp/awards/22daawards.